Clinical trial Recruiting at 1 site Observational Ages 18 and up

Ciprofol versus propofol for sedating adult ICU patients on noninvasive respiratory support

Official title: Comparison of the Efficacy and Safety of Ciprofol Versus Propofol for Sedation in ICU Patients Undergoing Non-Invasive Ventilation: A Multicenter Retrospective Cohort Study

Run by Nanfang Hospital, Southern Medical University · NCT07536750 · Data updated 2026-11-12

See if ciprofol works better than propofol for sedating adults in the ICU who are receiving noninvasive ventilation, high-flow nasal cannula, or oxygen therapy.

More Critical Illness trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1680 (estimated)
SponsorNanfang Hospital, Southern Medical University
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedNovember 24, 2025
Main results expectedJune 30, 2026
Study endsJune 30, 2026
Registry record updatedApril 17, 2026
Trial IDNCT07536750 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) admitted to the ICU at Nanfang Hospital between Jan 1, 2022 and Jul 30, 2024 who received at least two hours of intravenous ciprofol or propofol while on noninvasive ventilation, high-flow nasal cannula, or other oxygen therapy with complete RASS and continuous vital sign records.

Probably not a fit

Patients who are invasively ventilated, under 18, pregnant or breastfeeding, predominantly given other sedatives, or who lack complete sedation and monitoring records are unlikely to be included or to benefit from these findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational comparison of adults admitted to the ICU at Nanfang Hospital who received intravenous ciprofol or propofol for sedation while not invasively ventilated. Researchers will use electronic medical records from Jan 1, 2022 to Jul 30, 2024 to compare sedation depth (RASS), vital signs, respiratory events, hemodynamic instability, and need for escalation to endotracheal intubation. Patients must have received at least two hours of the index sedative and have continuous monitoring and complete sedation assessments. Safety endpoints will focus on respiratory depression, hypoxemia, hypotension, and sedation-related adverse events in the non-intubated ICU population.

Why it matters

Potential benefit: If ciprofol provides effective sedation with fewer respiratory or cardiovascular side effects, patients may tolerate noninvasive respiratory support better and have fewer emergency intubations.

How similar studies have gone: Propofol is well established for ICU sedation, whereas ciprofol is a newer agent with promising anesthesia data but limited comparative real-world ICU evidence to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria Age:

* Age ≥18 years
* Admitted to the intensive care unit (ICU) between January 1, 2022 and July 30, 2024
* Received intravenous sedation with either ciprofol or propofol during ICU stay
* Total duration of ciprofol or propofol administration ≥2 hours
* Sedation initiated while the patient was not receiving invasive mechanical ventilation
* Receiving non-invasive respiratory support or oxygen therapy at the time sedation was started, including noninvasive ventilation (NIV), high-flow nasal cannula (HFNC), nasal cannula, or face mask oxygen therapy
* Availability of complete electronic medical records including sedation assessment using the Richmond Agitation-Sedation Scale (RASS)
* Availability of continuous vital sign monitoring records including respiratory rate, oxygen saturation, blood pressure, and heart rate

Exclusion Criteria:

* Age \<18 years
* Pregnancy or breastfeeding
* Use of other primary sedative agents during the observation period, including midazolam or dexmedetomidine
* Total exposure time to ciprofol or propofol \<2 hours
* Known allergy or hypersensitivity to ciprofol, propofol, or their formulation components
* Initiation of invasive mechanical ventilation before sedation
* Missing key clinical data required for outcome evaluation, including sedation score, vital signs, or drug administration records
* Participation in other interventional clinical trials that may interfere with outcome assessment
* Severe visual or hearing impairment preventing accurate sedation assessment
* Coma or conditions that prevent reliable evaluation using the Richmond Agitation-Sedation Scale (RASS)
* Any condition that the investigators consider inappropriate for inclusion in the study

Where it's running

  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.